Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries: A Modeling Study

Research output: Contribution to journalJournal articleResearchpeer-review

  • Richard Osei-Yeboah
  • Caroline Klint Johannesen
  • Amanda Marie Egeskov-Cavling
  • Junru Chen
  • Toni Lehtonen
  • Arantxa Urchueguía Fornes
  • John Paget
  • Fischer, Thea Kølsen
  • Xin Wang
  • Harish Nair
  • Harry Campbell
  • Hanna Nohynek
  • Anne Teirlinck
  • Michiel van Boven
  • Terho Heikkinen
  • Louis Bont
  • Peter Openshaw
  • Phillipe Beutels
  • Andrew Pollard
  • Veena Kumar
  • Alexandro Orrico Sánchez
  • David Gideonse
  • Tin Tin Htar
  • Charlotte Vernhes
  • Gael Dos Santos
  • Rachel Cohen
  • Jeroen Aerssens
  • Rolf Kramer
  • Ombeline Jollivet
  • Nuria Manchin
  • PROMISE Investigators

Background. Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods. By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results. In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions. This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.

Original languageEnglish
JournalJournal of Infectious Diseases
Volume229
Pages (from-to)S70-S77
Number of pages8
ISSN0022-1899
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved.

    Research areas

  • adults, comorbidity, hospitalization, respiratory syncytial virus

ID: 387020483